EFTR (eFFECTOR Therapeutics) Total Stockholders Equity: $0.83 Mil (As of Mar. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is eFFECTOR Therapeutics Total Stockholders Equity?

eFFECTOR Therapeutics EFTR Total Stockholders Equity is $0.83 Mil as of Mar. 2024.

eFFECTOR Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $0.83 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. eFFECTOR Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $0.21. The ratio of a company's debt over equity can be used to measure how leveraged this company is. eFFECTOR Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 was 24.48.

eFFECTOR Therapeutics  (OTCPK:EFTR) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

eFFECTOR Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(0.827-0)/3.902
=0.21

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

eFFECTOR Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(20.069 + 0.179) / 0.827
=24.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

eFFECTOR Therapeutics Total Stockholders Equity Related Terms

eFFECTOR Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for eFFECTOR Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

eFFECTOR Therapeutics Total Stockholders Equity Chart

eFFECTOR Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
-132.25 17.28 3.90 -5.80

eFFECTOR Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.81 2.58 -3.97 -5.80 0.83
What does a Total Stockholders Equity of $0.83 Mil mean?
eFFECTOR Therapeutics (EFTR) has a Total Stockholders Equity of $0.83 Mil as of Mar. 2024. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for eFFECTOR Therapeutics and its competitors.
Is eFFECTOR Therapeutics' Total Stockholders Equity too high?
eFFECTOR Therapeutics' current Total Stockholders Equity is $0.83 Mil.
How does eFFECTOR Therapeutics' Total Stockholders Equity compare to NTBLQ and MTEM?
eFFECTOR Therapeutics' Total Stockholders Equity of $0.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for eFFECTOR Therapeutics and its competitors. eFFECTOR Therapeutics's current Total Stockholders Equity is $0.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is eFFECTOR Therapeutics stock overvalued right now?
eFFECTOR Therapeutics (EFTR) has a current Total Stockholders Equity of $0.83 Mil. The current Total Stockholders Equity is $0.83 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For eFFECTOR Therapeutics (EFTR), the current Total Stockholders Equity is $0.83 Mil as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

eFFECTOR Therapeutics Business Description

Address 142 North Cedros Avenue, Suite B, Solana Beach, CA, USA, 92075
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).